The 2nd Annual Gene Therapy Summit will take place June 7-9, 2022, in Boston, MA. With a focus on effectively engaging genetic therapy patients, this is a must attend summit for individuals and companies that are serious about building safer and more meaningful gene therapy programs. The summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers, patient groups and patients themselves to address the specific challenges of patient engagement in genetic therapy and will generate actionable insights through detailed case studies and open discussions.
As gene therapies proliferate and sector investment continues to grow rapidly, engaging with patients effectively at each stage of the processes has become a priority and a necessity to enhance efficacy.
During the comprehensive 3-day agenda you will hear directly from experts in patient advocacy at genetics companies including Spark Therapeutics, Ultragenyx, BioMarin, Global Genes, and CRISPR Therapeutics. Other speakers include Pfizer’s Senior Director of Policy & Public Affairs and the Deputy Director, Officer of Rare Diseases Research at NIH.
These speakers and others will address important topics that include managing expectations across gene therapy development, navigating patient input on one-time transformative treatments with novel clinical trial designs combined with extensive follow-ups, and developing educational materials on gene therapy to raise awareness in collaboration with patient advocacy organizations.
This is a unique opportunity to leverage the collective knowledge and experience of industry experts to ensure effective creation and implementation of patient-centric gene therapy programs.
Past attendees of the Gene Therapy Event Series have praised the event saying:
“Exciting new way of participating in scientific conference and discussion.” uniQure
“I found the presenters and participant patient engagement knowledge superb, as was their willingness to share.” 4D Molecular Therapeutics
“Incredibly positive and eye-opening experience for a scientist new to the field.” Novartis Gene Therapies
“Lots of useful information and good variety of perspectives.” Ten Bridge
The summit is hosted by Hanson Wade, a world leading conferences and data products organization that creates exclusive business conferences by gathering together the world’s smartest thinkers and doers.
Register here to attend https://genetherapy-patient-engagement.com/take-part/register/.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com